Claudin-low bladder tumors are immune infiltrated and actively immune suppressed

We report the discovery of a claudin-low molecular subtype of high-grade bladder cancer that shares characteristics with the homonymous subtype of breast cancer. Claudin-low bladder tumors were enriched for multiple genetic features including increased rates of , , and mutations; increased frequency...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JCI insight 2016-03, Vol.1 (3), p.e85902-e85902
Hauptverfasser: Kardos, Jordan, Chai, Shengjie, Mose, Lisle E, Selitsky, Sara R, Krishnan, Bhavani, Saito, Ryoichi, Iglesia, Michael D, Milowsky, Matthew I, Parker, Joel S, Kim, William Y, Vincent, Benjamin G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e85902
container_issue 3
container_start_page e85902
container_title JCI insight
container_volume 1
creator Kardos, Jordan
Chai, Shengjie
Mose, Lisle E
Selitsky, Sara R
Krishnan, Bhavani
Saito, Ryoichi
Iglesia, Michael D
Milowsky, Matthew I
Parker, Joel S
Kim, William Y
Vincent, Benjamin G
description We report the discovery of a claudin-low molecular subtype of high-grade bladder cancer that shares characteristics with the homonymous subtype of breast cancer. Claudin-low bladder tumors were enriched for multiple genetic features including increased rates of , , and mutations; increased frequency of amplification; decreased rates of , , and mutations; and decreased frequency of amplification. While claudin-low tumors showed the highest expression of immune gene signatures, they also demonstrated gene expression patterns consistent with those observed in active immunosuppression. This did not appear to be due to differences in predicted neoantigen burden, but rather was associated with broad upregulation of cytokine and chemokine levels from low activity, allowing unopposed activity. Taken together, these results define a molecular subtype of bladder cancer with distinct molecular features and an immunologic profile that would, in theory, be primed for immunotherapeutic response.
doi_str_mv 10.1172/jci.insight.85902
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5033914</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1835357905</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-bf345e5f098de9e141619508661ffeb036bb90269da0eb62de073fa727e9fce03</originalsourceid><addsrcrecordid>eNpVUclOwzAQtRCIVoUP4IJy5JJix7EdX5BQxSZVggOcLSceg5GzYCdF_XsCXVQOozfSvHmzPIQuCJ4TIrLrz8rNXRPd-0c_L5jE2RGaZlTIlApcHB_kE3Qe4yfGmIg8w6w4RZNMcCkzxqfoZeH1YFyT-vY7Kb02BkLSD3UbYqIDJK6uh2aExjrfB92DSXQzRtW7Ffj1rh6HrgsQI5gzdGK1j3C-xRl6u797XTymy-eHp8XtMq1yLvu0tDRnwCyWhQEJJCecSIYLzom1UGLKy3K8iUujMZQ8M4AFtVpkAqStANMZutnodkNZg6mgGdfzqguu1mGtWu3U_0rjPtR7u1IMUypJPgpcbQVC-zVA7FXtYgXe6wbaISpSUEaZkJiNVLKhVqGNMYDdjyFY_ZqhRjPU1gz1Z8bYc3m4375j93r6A-s-iu0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835357905</pqid></control><display><type>article</type><title>Claudin-low bladder tumors are immune infiltrated and actively immune suppressed</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Kardos, Jordan ; Chai, Shengjie ; Mose, Lisle E ; Selitsky, Sara R ; Krishnan, Bhavani ; Saito, Ryoichi ; Iglesia, Michael D ; Milowsky, Matthew I ; Parker, Joel S ; Kim, William Y ; Vincent, Benjamin G</creator><creatorcontrib>Kardos, Jordan ; Chai, Shengjie ; Mose, Lisle E ; Selitsky, Sara R ; Krishnan, Bhavani ; Saito, Ryoichi ; Iglesia, Michael D ; Milowsky, Matthew I ; Parker, Joel S ; Kim, William Y ; Vincent, Benjamin G</creatorcontrib><description>We report the discovery of a claudin-low molecular subtype of high-grade bladder cancer that shares characteristics with the homonymous subtype of breast cancer. Claudin-low bladder tumors were enriched for multiple genetic features including increased rates of , , and mutations; increased frequency of amplification; decreased rates of , , and mutations; and decreased frequency of amplification. While claudin-low tumors showed the highest expression of immune gene signatures, they also demonstrated gene expression patterns consistent with those observed in active immunosuppression. This did not appear to be due to differences in predicted neoantigen burden, but rather was associated with broad upregulation of cytokine and chemokine levels from low activity, allowing unopposed activity. Taken together, these results define a molecular subtype of bladder cancer with distinct molecular features and an immunologic profile that would, in theory, be primed for immunotherapeutic response.</description><identifier>ISSN: 2379-3708</identifier><identifier>EISSN: 2379-3708</identifier><identifier>DOI: 10.1172/jci.insight.85902</identifier><identifier>PMID: 27699256</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject>Antigens, Neoplasm - metabolism ; Chemokines - immunology ; Claudins - genetics ; Cytokines - immunology ; Humans ; Immune Tolerance ; Leukocytes - immunology ; NF-kappa B - metabolism ; PPAR gamma - metabolism ; Tumor Microenvironment ; Urinary Bladder Neoplasms - classification ; Urinary Bladder Neoplasms - genetics ; Urinary Bladder Neoplasms - immunology</subject><ispartof>JCI insight, 2016-03, Vol.1 (3), p.e85902-e85902</ispartof><rights>Copyright © 2016, American Society for Clinical Investigation 2016 American Society for Clinical Investigation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-bf345e5f098de9e141619508661ffeb036bb90269da0eb62de073fa727e9fce03</citedby><cites>FETCH-LOGICAL-c469t-bf345e5f098de9e141619508661ffeb036bb90269da0eb62de073fa727e9fce03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033914/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033914/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27699256$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kardos, Jordan</creatorcontrib><creatorcontrib>Chai, Shengjie</creatorcontrib><creatorcontrib>Mose, Lisle E</creatorcontrib><creatorcontrib>Selitsky, Sara R</creatorcontrib><creatorcontrib>Krishnan, Bhavani</creatorcontrib><creatorcontrib>Saito, Ryoichi</creatorcontrib><creatorcontrib>Iglesia, Michael D</creatorcontrib><creatorcontrib>Milowsky, Matthew I</creatorcontrib><creatorcontrib>Parker, Joel S</creatorcontrib><creatorcontrib>Kim, William Y</creatorcontrib><creatorcontrib>Vincent, Benjamin G</creatorcontrib><title>Claudin-low bladder tumors are immune infiltrated and actively immune suppressed</title><title>JCI insight</title><addtitle>JCI Insight</addtitle><description>We report the discovery of a claudin-low molecular subtype of high-grade bladder cancer that shares characteristics with the homonymous subtype of breast cancer. Claudin-low bladder tumors were enriched for multiple genetic features including increased rates of , , and mutations; increased frequency of amplification; decreased rates of , , and mutations; and decreased frequency of amplification. While claudin-low tumors showed the highest expression of immune gene signatures, they also demonstrated gene expression patterns consistent with those observed in active immunosuppression. This did not appear to be due to differences in predicted neoantigen burden, but rather was associated with broad upregulation of cytokine and chemokine levels from low activity, allowing unopposed activity. Taken together, these results define a molecular subtype of bladder cancer with distinct molecular features and an immunologic profile that would, in theory, be primed for immunotherapeutic response.</description><subject>Antigens, Neoplasm - metabolism</subject><subject>Chemokines - immunology</subject><subject>Claudins - genetics</subject><subject>Cytokines - immunology</subject><subject>Humans</subject><subject>Immune Tolerance</subject><subject>Leukocytes - immunology</subject><subject>NF-kappa B - metabolism</subject><subject>PPAR gamma - metabolism</subject><subject>Tumor Microenvironment</subject><subject>Urinary Bladder Neoplasms - classification</subject><subject>Urinary Bladder Neoplasms - genetics</subject><subject>Urinary Bladder Neoplasms - immunology</subject><issn>2379-3708</issn><issn>2379-3708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUclOwzAQtRCIVoUP4IJy5JJix7EdX5BQxSZVggOcLSceg5GzYCdF_XsCXVQOozfSvHmzPIQuCJ4TIrLrz8rNXRPd-0c_L5jE2RGaZlTIlApcHB_kE3Qe4yfGmIg8w6w4RZNMcCkzxqfoZeH1YFyT-vY7Kb02BkLSD3UbYqIDJK6uh2aExjrfB92DSXQzRtW7Ffj1rh6HrgsQI5gzdGK1j3C-xRl6u797XTymy-eHp8XtMq1yLvu0tDRnwCyWhQEJJCecSIYLzom1UGLKy3K8iUujMZQ8M4AFtVpkAqStANMZutnodkNZg6mgGdfzqguu1mGtWu3U_0rjPtR7u1IMUypJPgpcbQVC-zVA7FXtYgXe6wbaISpSUEaZkJiNVLKhVqGNMYDdjyFY_ZqhRjPU1gz1Z8bYc3m4375j93r6A-s-iu0</recordid><startdate>20160317</startdate><enddate>20160317</enddate><creator>Kardos, Jordan</creator><creator>Chai, Shengjie</creator><creator>Mose, Lisle E</creator><creator>Selitsky, Sara R</creator><creator>Krishnan, Bhavani</creator><creator>Saito, Ryoichi</creator><creator>Iglesia, Michael D</creator><creator>Milowsky, Matthew I</creator><creator>Parker, Joel S</creator><creator>Kim, William Y</creator><creator>Vincent, Benjamin G</creator><general>American Society for Clinical Investigation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160317</creationdate><title>Claudin-low bladder tumors are immune infiltrated and actively immune suppressed</title><author>Kardos, Jordan ; Chai, Shengjie ; Mose, Lisle E ; Selitsky, Sara R ; Krishnan, Bhavani ; Saito, Ryoichi ; Iglesia, Michael D ; Milowsky, Matthew I ; Parker, Joel S ; Kim, William Y ; Vincent, Benjamin G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-bf345e5f098de9e141619508661ffeb036bb90269da0eb62de073fa727e9fce03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antigens, Neoplasm - metabolism</topic><topic>Chemokines - immunology</topic><topic>Claudins - genetics</topic><topic>Cytokines - immunology</topic><topic>Humans</topic><topic>Immune Tolerance</topic><topic>Leukocytes - immunology</topic><topic>NF-kappa B - metabolism</topic><topic>PPAR gamma - metabolism</topic><topic>Tumor Microenvironment</topic><topic>Urinary Bladder Neoplasms - classification</topic><topic>Urinary Bladder Neoplasms - genetics</topic><topic>Urinary Bladder Neoplasms - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kardos, Jordan</creatorcontrib><creatorcontrib>Chai, Shengjie</creatorcontrib><creatorcontrib>Mose, Lisle E</creatorcontrib><creatorcontrib>Selitsky, Sara R</creatorcontrib><creatorcontrib>Krishnan, Bhavani</creatorcontrib><creatorcontrib>Saito, Ryoichi</creatorcontrib><creatorcontrib>Iglesia, Michael D</creatorcontrib><creatorcontrib>Milowsky, Matthew I</creatorcontrib><creatorcontrib>Parker, Joel S</creatorcontrib><creatorcontrib>Kim, William Y</creatorcontrib><creatorcontrib>Vincent, Benjamin G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>JCI insight</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kardos, Jordan</au><au>Chai, Shengjie</au><au>Mose, Lisle E</au><au>Selitsky, Sara R</au><au>Krishnan, Bhavani</au><au>Saito, Ryoichi</au><au>Iglesia, Michael D</au><au>Milowsky, Matthew I</au><au>Parker, Joel S</au><au>Kim, William Y</au><au>Vincent, Benjamin G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Claudin-low bladder tumors are immune infiltrated and actively immune suppressed</atitle><jtitle>JCI insight</jtitle><addtitle>JCI Insight</addtitle><date>2016-03-17</date><risdate>2016</risdate><volume>1</volume><issue>3</issue><spage>e85902</spage><epage>e85902</epage><pages>e85902-e85902</pages><issn>2379-3708</issn><eissn>2379-3708</eissn><abstract>We report the discovery of a claudin-low molecular subtype of high-grade bladder cancer that shares characteristics with the homonymous subtype of breast cancer. Claudin-low bladder tumors were enriched for multiple genetic features including increased rates of , , and mutations; increased frequency of amplification; decreased rates of , , and mutations; and decreased frequency of amplification. While claudin-low tumors showed the highest expression of immune gene signatures, they also demonstrated gene expression patterns consistent with those observed in active immunosuppression. This did not appear to be due to differences in predicted neoantigen burden, but rather was associated with broad upregulation of cytokine and chemokine levels from low activity, allowing unopposed activity. Taken together, these results define a molecular subtype of bladder cancer with distinct molecular features and an immunologic profile that would, in theory, be primed for immunotherapeutic response.</abstract><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>27699256</pmid><doi>10.1172/jci.insight.85902</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2379-3708
ispartof JCI insight, 2016-03, Vol.1 (3), p.e85902-e85902
issn 2379-3708
2379-3708
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5033914
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Antigens, Neoplasm - metabolism
Chemokines - immunology
Claudins - genetics
Cytokines - immunology
Humans
Immune Tolerance
Leukocytes - immunology
NF-kappa B - metabolism
PPAR gamma - metabolism
Tumor Microenvironment
Urinary Bladder Neoplasms - classification
Urinary Bladder Neoplasms - genetics
Urinary Bladder Neoplasms - immunology
title Claudin-low bladder tumors are immune infiltrated and actively immune suppressed
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T08%3A27%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Claudin-low%20bladder%20tumors%20are%20immune%20infiltrated%20and%20actively%20immune%20suppressed&rft.jtitle=JCI%20insight&rft.au=Kardos,%20Jordan&rft.date=2016-03-17&rft.volume=1&rft.issue=3&rft.spage=e85902&rft.epage=e85902&rft.pages=e85902-e85902&rft.issn=2379-3708&rft.eissn=2379-3708&rft_id=info:doi/10.1172/jci.insight.85902&rft_dat=%3Cproquest_pubme%3E1835357905%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835357905&rft_id=info:pmid/27699256&rfr_iscdi=true